Gauging the Impact of Artificial Intelligence and Mathematical Modeling in Response to the COVID-19 Pandemic: A Systematic ReviewCOVID-19 팬데믹에 대응하여 인공 지능 및 수학적 모델링의 영향 측정: 체계적인 검토Article Published on 2022-03-142022-09-11 Journal: BioMed Research International [Category] SARS, 변종, [키워드] Accuracy Analysis analyzed ARIMA article articles artificial AstraZeneca AUC B.1.1.7 B.1.617.2 Beta BNT162b2 booster dose booster doses conducted COVID-19 COVID-19 virus data-driven Delta Effect Effectiveness Evolution groups hybrid Impact initial intelligence literature review machine learning models mathematical mitigate modeling Moderna mRNA mRNA-1273 Pfizer-BioNTech Precision Predictive model predictive models Prevent Quality researcher response review selected sensitivity specificity Spread spread of COVID-19 validation cohort viral variant Viral variants virus were used while [DOI] 10.1155/2022/7731618 PMC 바로가기 [Article Type] Article
Effectiveness of Covid-19 Vaccines over a 9-Month Period in North Carolina노스캐롤라이나에서 9개월 동안의 Covid-19 백신의 효과Article Published on 2022-03-102022-09-11 Journal: The New England Journal of Medicine [Category] SARS, 변종, [키워드] 95% CI 95% confidence interval Ad26 Ad26.COV2.S B.1.617.2 BNT162b2 caused coronavirus disease Coronavirus disease 2019 COV2.S Cox regression model death declining delta variant dominant dose Effectiveness elapsed first dose Hospitalization Immunity increase in Infection Messenger RNA Moderna mRNA mRNA vaccine mRNA-1273 North of BNT162b2 outcome Period Pfizer-BioNTech postvaccination preventing infection provided recipient reducing regimen risk summer System the United State two-dose regimen United States vaccination Vaccine variant Viral particles [DOI] 10.1056/NEJMoa2117128 PMC 바로가기 [Article Type] Article
Comparison of Moderna versus Pfizer-BioNTech COVID-19 vaccine outcomes: A target trial emulation study in the U.S. Veterans Affairs healthcare systemResearch article Published on 2022-03-052022-10-05 Journal: EClinicalMedicine [Category] 임상, [키워드] 95% CI adjusted hazard ratio Affair age all age groups analyzed BNT162b2 category clinical trials Comorbidity COVID-19 vaccination COVID-19 vaccine death delta variant Department Electronic health records finding follow-up period follow-up time funding greater Healthcare system Hospitalization Infection less Medicare Moderna mRNA COVID-19 vaccine mRNA-1273 National occurred outcome Pfizer-BioNTech predominant propensity score matching rates of infection recipient recipients risk risk of infection SARS-COV-2 infection SARS-CoV-2 infections shown significantly lower statistically significant the vaccine Trial vaccination Vaccine vaccine dose vaccine group veteran [DOI] 10.1016/j.eclinm.2022.101326 [Article Type] Research article
Real-world serological responses to extended-interval and heterologous COVID-19 mRNA vaccination in frail, older people (UNCoVER): an interim report from a prospective observational cohort studyObservational Study Published on 2022-03-012022-10-05 Journal: The Lancet. Healthy longevity [Category] COVID19(2023년), SARS, 임상, 진단, [키워드] Abstract Administered administration age anti-RBD Anti-RBD IgG anti-Spike IgG Anti-spike IgG responses antibody Antibody Response antigenicity automated baseline binding antibody unit blood sample BNT162b2 BNT162b2 vaccine boost Canada Care clinical clinically Cohort cohorts collected combinations Comorbidity Concentration COVID-19 COVID-19 mRNA Vaccination COVID-19 vaccine decrease distribution dose doses Effectiveness eligible ELISA enrolled extended-interval first dose fluctuation for inclusion force French Government Heterologous heterologous prime-boost homologous or heterologous individual infected individual Interim Interim report log material Moderna mRNA vaccine mRNA vaccines mRNA-1273 mRNA-1273 vaccine mRNA-based COVID-19 vaccine nucleocapsid protein of BNT162b2 Older participant Participants Pfizer-BioNTech prime and boost prospective observational cohort PROTECT Public reference response SARS-COV-2 infection SARS-CoV-2-specific IgG second dose serological response service significant difference significant increase tested the receptor-binding domain the spike protein timepoint translation Trimeric spike protein university Vaccine vaccine availability vaccine dose Vaccines was done were used [DOI] 10.1016/S2666-7568(22)00012-5 PMC 바로가기 [Article Type] Observational Study
Incidence and Characteristics of Delayed Injection Site Reaction to the mRNA-1273 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccine (Moderna) in a Cohort of Hospital EmployeesObservational Study Published on 2022-03-012022-10-05 Journal: Clinical Infectious Diseases: An Official Publicat [Category] SARS, 임상, [키워드] Administered administration adverse effect BNT162b cohort study coronavirus 2 COVID-19 Delayed dose drug Emergency use authorization employee female females food hospital individual initial initiated injection injection site reaction male Moderna mRNA mRNA vaccination mRNA-1273 mRNA-1273 vaccine occur per day Pfizer Rash rashe reaction Reactions reported respiratory San Francisco SARS-CoV-2 SARS-CoV-2 vaccine second dose Serious Adverse Event Sex Site Symptom the SARS-CoV-2 the United State vaccination Vaccine vaccine dose [DOI] 10.1093/cid/ciab518 PMC 바로가기 [Article Type] Observational Study
SARS-CoV-2 Breakthrough Infections after introduction of 4 COVID-19 Vaccines, South Korea, 2021Research Letter Published on 2022-03-012022-10-31 Journal: Emerging Infectious Diseases [Category] COVID-19, MERS, SARS, [키워드] acute respiratory syndrome AstraZeneca breakthrough Breakthrough infection conducted coronavirus coronavirus disease COVID-19 highest janssen Moderna Pfizer-BioNTech recipient respiratory infections retrospective cohort study SARS-CoV-2 severe acute respiratory syndrome coronavirus 2 South Korea Vaccine viruses zoonoses [DOI] 10.3201/eid2803.212210 PMC 바로가기 [Article Type] Research Letter
CD4 + T cells from COVID-19 mRNA vaccine recipients recognize a conserved epitope present in diverse coronavirusesClinical Trial Published on 2022-03-012022-10-04 Journal: The Journal of Clinical Investigation [Category] MERS, SARS, 임상, [키워드] Adaptive immunity assays bat coronavirus bat coronaviruses BNT162b2 CD4 common cold Coronaviruses conserved coronavirus Coronaviruses COVID-19 COVID-19 vaccines demonstrated elicit Endemic epitope homologous Hypothesis induce majority MERS-CoV Moderna mRNA vaccine mRNA-1273 Outbreaks Pandemics participant peptide Pfizer-BioNTech recent recipient recognize Responder SARS-CoV SARS-CoV-2 SARS-CoV-2 spike protein Sequencing shown Support T cell T cell receptor T cell response vaccinated individual Vaccine zoonotic [DOI] 10.1172/JCI156083 PMC 바로가기 [Article Type] Clinical Trial
Effectiveness of 3 COVID-19 Vaccines in Preventing SARS-CoV-2 Infections, January–May 2021, Aragon, SpainResearch Published on 2022-03-012022-10-31 Journal: Emerging Infectious Diseases [Category] COVID-19, MERS, SARS, [키워드] 95% CI acute respiratory syndrome conducted coronavirus coronavirus disease Coverage COVID-19 COVID-19 vaccines Cox proportional-hazards model Critical disease dose doses Effectiveness estimate Infection Moderna Oxford-AstraZeneca Pfizer-BioNTech population-based cohort Preventing Previous studies PROTECT respiratory infections Result SARS-CoV-2 SARS-COV-2 infection severe acute respiratory syndrome coronavirus disease 2 Spain Transmission treatment outcomes vaccination Vaccine vaccine effectiveness viruses widespread zoonoses [DOI] 10.3201/eid2803.212027 PMC 바로가기 [Article Type] Research
Immunogenicity and tolerability of COVID-19 messenger RNA vaccines in primary immunodeficiency patients with functional B-cell defects기능적 B 세포 결함이 있는 원발성 면역결핍 환자에서 코로나19 메신저 RNA 백신의 면역원성과 내약성Multicenter Study Published on 2022-03-012022-09-11 Journal: The Journal of Allergy and Clinical Immunology [Category] MERS, SARS, 진단, 치료기술, [키워드] ACE2 ACE2 blocking antibody ACE2 receptor acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 angiotensin Angiotensin-converting enzyme angiotensin-converting enzyme 2 antibody Antibody deficiency Antibody Response Antibody responses B-cell blocking activity blocking antibody BNT162b2 BNT162b2 vaccine cellular immunity Clinical management cohort of patient common variable immunodeficiency coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 mRNA Vaccination COVID-19 vaccine trials detectable dose effective Efficacy enzyme evaluated functional Good Good syndrome help humoral Humoral response humoral responses IFN-γ IgG antibody IgG responses immune responses immunodeficiency immunogenicity information less mAb Messenger RNA Moderna mRNA mRNA vaccine mRNA vaccines mRNA-1273 neutralization not effective Patient patients Pfizer-BioNTech PID PIDs positive Primary immunodeficiencies Primary Immunodeficiency RBD RBD binding RBD-specific IgG responses Reactions reactogenicity Receptor binding domain referred to respiratory retrospective retrospective review Safe SARS-CoV-2 SARS-CoV-2 IFN-γ release assay SARS-CoV-2 spike protein SARS-CoV-2 spike protein antibody SARS-CoV-2 spike protein receptor binding domain SARS-CoV-2 vaccination severe acute respiratory syndrome Coronavirus Spike protein spike protein RBD stimulated subject subjects T-cell immune response T-cell Response the spike protein Tolerability vaccination Vaccine was performed were excluded with COVID-19 [DOI] 10.1016/j.jaci.2021.11.022 PMC 바로가기 [Article Type] Multicenter Study
COVID-19 Vaccination Effectiveness Against Infection or Death in a National U.S. Health Care System : A Target Trial Emulation Study미국 국립 의료 시스템의 감염 또는 사망에 대한 COVID-19 예방 접종 효과 : 표적 시험 에뮬레이션 연구Article Published on 2022-03-012022-09-11 Journal: Annals of internal medicine [Category] SARS, 변종, [키워드] 1:1 95% CI advanced age Affair Against black both groups Care Characteristics Comorbidity Control controls COVID-19 COVID-19 vaccine COVID-19 vaccines death defined Department determine distribution dose Effectiveness effort example Follow-up group Health Health care Health care system Hispanic in both groups increasing age Infection lack male Messenger RNA Moderna pandemic Pfizer-BioNTech Population Racial receiving reported SARS-COV-2 infection SARS-CoV-2 variants System target Trial vaccination vaccine dose veteran [DOI] 10.7326/M21-3256 PMC 바로가기 [Article Type] Article